vTv Therapeutics Inc
$ 35.13
2.43%
23 Feb - close price
- Market Cap 138,362,000 USD
- Current Price $ 35.13
- High / Low $ 35.91 / 34.00
- Stock P/E N/A
- Book Value 5.68
- EPS -3.30
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.64 %
- 52 Week High 44.00
- 52 Week Low 14.00
About
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.
Analyst Target Price
$51.20
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-12 | 2025-05-07 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-11 | 2023-05-11 | 2023-03-06 |
| Reported EPS | -1.08 | -0.92 | -0.77 | -0.552 | -0.8766 | -0.8089 | -1.1747 | -1.67 | -3.2 | -0.07 | -0.06 | -0.06 |
| Estimated EPS | -1 | -1.12 | -0.815 | -0.87 | None | None | None | -0.07 | -0.08 | -0.07 | -0.09 | -0.06 |
| Surprise | -0.08 | 0.2 | 0.045 | 0.318 | 0 | 0 | 0 | -1.6 | -3.12 | 0 | 0.03 | 0 |
| Surprise Percentage | -8% | 17.8571% | 5.5215% | 36.5517% | None% | None% | None% | -2285.7143% | -3900% | 0% | 33.3333% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.98 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTVT
2026-02-13 17:23:59
vTv Therapeutics, a biopharmaceutical company specializing in diabetes treatment, announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. Management will present information on its lead candidate, cadisegliatin, an oral adjunctive therapy for type 1 diabetes currently in a US Phase 3 trial.
2026-02-13 13:03:00
vTv Therapeutics Inc. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. The company will present on its lead clinical candidate, cadisegliatin, a potential first-in-class oral adjunctive therapy in Phase 3 trials for type 1 diabetes. Cadisegliatin has received Breakthrough Therapy designation from the FDA.
2026-02-13 12:57:39
vTv Therapeutics, a late-stage biopharmaceutical company, announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. Management will provide presentations on their pipeline, which includes cadisegliatin, a potential first-in-class oral treatment for type 1 diabetes, currently in a US Phase 3 trial.
2026-02-13 12:57:39
vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on developing cadisegliatin for type 1 diabetes, announced its management will participate in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Both events will include presentations, with webcasts available, and the TD Cowen conference will also feature 1x1 meetings.
2026-02-13 08:00:00
vTv Therapeutics announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The company will present on its lead clinical candidate, cadisegliatin, an oral adjunctive therapy being investigated for type 1 diabetes. This highlights vTv Therapeutics' efforts to engage with investors and advance its pipeline.
2026-02-13 08:00:00
vTv Therapeutics announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Management will present at both virtual and in-person events to discuss the company's progress, particularly concerning cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes.
